about
Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas.Epigenetic silencing of miR-145-5p contributes to brain metastasisIntraoperative radiation therapy as adjuvant treatment in locally advanced stage tumours involving the middle ear: a hypothesis-generating retrospective studyBrain stereotactic biopsy flow cytometry for central nervous system lymphoma characterization: advantages and pitfalls.Surgery of malignant gliomas: advances and perspectives.Radionecrosis induced by stereotactic radiosurgery of brain metastases: results of surgery and outcome of disease.Spine Surgery in Patients with Metastatic Breast Cancer: A Retrospective Analysis.Home palliative care and end of life issues in glioblastoma multiforme: results and comments from a homogeneous cohort of patients.MicroRNA-128-3p-mediated depletion of Drosha promotes lung cancer cell migration.Unilateral Laminectomy Approach for the Removal of Spinal Meningiomas and Schwannomas: Impact on Pain, Spinal Stability, and Neurologic ResultsKyphoplasty with purified silicone VK100 (Elastoplasty) to treat spinal lytic lesions in cancer patients: A retrospective evaluation of 41 casesComorbidities in elderly patients with glioblastoma: a field-practice studyHow is stereotactic brain biopsy evolving? A multicentric analysis of a series of 421 cases treated in Rome over the last sixteen yearsNeurocognitive evaluation in older adult patients affected by gliomaOpen Kyphoplasty for Metastatic Spine Disease: A Retrospective Clinical SeriesA multicenter real-world study of bevacizumab in heavily pretreated malignant gliomas: clinical benefit is a plausible end point?
P50
Q33625227-691A3723-0C20-496A-B6CC-EE5F0250B98FQ36546293-3DE9392D-886E-4B23-BC56-F3F3DC935375Q37002365-1BD1F2AB-CC68-4059-B347-8D9FB61F699CQ37212272-BA1C1FE4-5E47-49A0-AB19-A65030F3368EQ37920669-B6346EBE-9612-41CE-A6E8-DB1D4D5F7D4AQ38092731-039E11B8-2245-470C-AFD7-B5FD6041B2A7Q38746971-EDB2B8DB-884B-49C1-B054-618E5146FF15Q48058581-6F66CC02-74DD-48D5-B4DC-0E7EAC11666DQ53179822-9A3A67B3-DF0D-41D8-A751-1CF76B4D21FFQ86502030-45A6E018-6636-4654-ACA4-876D42A7E55FQ89179491-D959ACC4-C768-4F9B-9291-6FCE24EF5B9AQ91106430-073B5AD0-6DBC-4D51-A03D-13D7FBF91B95Q91509985-2A7EBCCD-FBD2-4041-8DE0-7B8BBB65ED20Q91662752-D11F65D6-5628-4F11-950F-EDEDD60C0D69Q92879602-A542CF16-4D0F-49F6-888D-E813BB876A2EQ93052157-ED9C0D93-5C0D-403C-A340-89C3BBEED9B5
P50
description
investigador
@es
researcher
@en
name
Stefano Telera
@en
type
label
Stefano Telera
@en
prefLabel
Stefano Telera
@en
P31
P496
0000-0002-1239-7143